- Marco Cavaleri, the European Medicines Agency’s (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been “rather disappointing.”
- The European average rate of receiving booster doses was only 29% in the groups considered to be at the highest risk.
- Though there have not been major increases in COVID-19 case rates in recent weeks, Cavaleri said that could change during the colder winter months, Reuters writes.
- Related: Don’t Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain’s NICE Says.
- World Health Organization data showed 724,000 new COVID-19 cases were reported in the EU over the past week, down 11% from the previous week.
- When experts warned of a new COVID-19 wave in early October, weekly cases reached 1.5 million.
- Cavaleri added that available antibody treatments are no longer working against new subvariants.
- The EMA intends to issue new guidelines for healthcare providers on the issue of such treatments, he said.
- At a December meeting with the FDA and other international experts, the EU regulator would discuss this issue, including clinical trial design of next-generation treatments.
- Pfizer Inc’s PFE has shown effectiveness against all COVID-19 variants and subvariants. But prompt access to Paxlovid remains an issue in the EU.
- Photo by Johaehn from Pixabay
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.